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Abstract
Background: The acquisition of needle-stick injuries (NSI) in a healthcare setting poses an occupational hazard of
transmitting blood-borne pathogens from patients to healthcare workers (HCWs). The objective of this study was to
systematically review the evidence about the efficacy and safety of using safety-engineered intravenous devices
and safety-engineered phlebotomy devices by HCWs.
Methods: We included randomized and non-randomized studies comparing safety-engineered devices to conventional/
standard devices that lack safety features for delivering intravenous injections and/or for blood-withdrawal procedures
(phlebotomy). The outcomes of interest included NSI rates, and blood-borne infections rates among HCWs and patients.
We conducted an extensive literature search strategy using the OVID interface in October 2013. We followed the standard
methods for study selection and data abstraction. When possible, we conducted meta-analyses using a random-effects
model. We used the GRADE methodology to assess the quality of evidence by outcome.
Results: We identified twenty-two eligible studies: Twelve assessed safety-engineered devices for intravenous
procedures, five
for phlebotomy procedures, and five for both. Twenty-one of those studies were observational while one was a
randomized trial. All studies assessed the reduction in NSIs among HCWs. For safety-engineered intravenous devices, the
pooled relative risk for NSI per HCW was 0.28 [0.13, 0.59] (moderate quality evidence). The pooled relative risk for NSI per
device used or procedure performed was 0.34 [0.08,1.49] (low quality evidence). For safety-engineered phlebotomy
devices, the pooled relative risk for NSI per HCW was 0.57 [0.38, 0.84] (moderate quality evidence). The pooled relative risk
for NSI per device used or procedure performed was 0.53 [0.43,0.65] (moderate quality evidence). We identified no studies
assessing the outcome of blood-borne infections among healthcare workers or patients.
Conclusion: There is moderate-quality evidence that the use of safety-engineered devices in intravenous injections and
infusions, and phlebotomy (blood-drawing) procedures reduces NSI rates of HCWs.
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Background
Healthcare workers (HCWs) worldwide face the serious
occupational health hazard of sharps injuries, commonly
referred to as Needle-Stick Injuries (NSIs) [1]. According
to the World Health Organization (WHO), there are
approximately two million occupational exposures to
blood-borne pathogens per year out of the total 35
million estimated HCWs worldwide [2]. In the United
States, it was estimated that about 384,325 NSIs occur
annually in hospital-based health-care personnel [3].
These injuries account for about one third of all occupa-
tional accidents encountered by HCWs in a healthcare
setting [4].
Phlebotomy (blood-drawing) procedures alone account
for 13 to 62 % of the injuries reported to the Hospital
Occupational Health Services [5, 6]. The annual
incidence rate of injuries amongst phlebotomists is
about 407 per 1000 HCWs, with these blood-drawing
procedures accounting for an estimate of 13.3 % of total
reported injuries [7]. Similarly, intravenous-access proce-
dures such as the administration of parenteral injections
and infusion therapies account for 15.7 % of all reported
injuries [7]. In short, blood-involving procedures have
higher risks of transferring blood-borne infections than
other procedures [8, 9].
Needle-stick injuries are hazardous due to their potential
for transmission of blood-borne pathogens, particularly
hepatitis B virus (HBV), hepatitis C virus (HCV), and
human immunodeficiency virus (HIV) [10, 11]. Indeed,
about 40 % of each of HBV and HCV reported cases and
about 4.4 % of HIV acquisitions in HCWs are attributable
to NSIs [2]. The risk of transmission following a percutan-
eous injury is 35 % for HBV, 3 to 10 % for HCV, and 0.2 to
0.5 % for HIV [12]. A study published in 2005 reported
that up to that date, approximately 66,000, 16,000, and
1000 global HCWs got infected with HBV, HCV, and HIV
respectively, due to sharps injuries alone [13].
Safety needle devices possess built-in safety controls
that reduce and potentially prevent NSIs [14]. These
devices allow needle-safe IV insertion and delivery,
blood collection, and intramuscular, intra-dermal and
subcutaneous injections [3, 15–17]. We have already
systematically reviewed the evidence for intramuscular,
intra-dermal and subcutaneous injections (under review
for publication). Although individual studies have found
a decrease in the number of percutaneous injuries
occurring during phlebotomy procedures [17] and
intravenous injections [3, 18] upon the use of safety-
engineered devices, no reviews to date have analyzed the
efficacy of such devices across studies using meta-
analysis techniques.
We conducted this study was to gather the evidence ne-
cessary for the development by WHO of a policy guidance
on use of safety-engineered devices by healthcare workers
to deliver a number of procedures, including intravenous
and/or phlebotomy procedures. The objective was to
systematically review the evidence about the efficacy and
safety of using safety-engineered intravenous devices and
safety-engineered phlebotomy devices by HCWs in
reducing NSIs and/or infection transmission rates.
We opted to review this evidence separately from that
of intramuscular and subcutaneous devices whose review
we published a while ago [19], for a number of reasons.
First, the two types of devices are not interchangeable,
so it reasonable to expect that their effects might not be
the same. Second, intravenous and phlebotomy devices
are associated with a higher rate of infection, compared
with intramuscular and subcutaneous devices, given they
come in direct contact with blood [20, 21]. Third, very
few studies have assessed the two types of devices
together. Even those that did, presented the data for the
two types of devices separately. Finally, the WHO that
commissioned this work was only interested in the
evidence for intramuscular and subcutaneous devices.
The specific questions were:
1. What is the efficacy of safety-engineered intravenous
devices versus conventional intravenous devices in
preventing accidental needle stick injuries when
used by HCWs in a health-care setting to perform
infusion therapies, and/or intravenous drug
administration?
2. What is the efficacy of safety-engineered phlebotomy
(blood-withdrawal) devices versus conventional
phlebotomy devices in preventing accidental needle
stick injuries when used by HCWs in a health-care
setting to withdraw blood from patients?
Methods
While we did not develop a protocol specifically for this
systematic review, we based our work on a protocol pre-
viously developed for a systematic review on sharp injury
prevention syringes for intramuscular, subcutaneous,
and intradermal injections [22]. This study adhered to
the PRISMA guidelines [23].
Eligibility criteria
Types of studies included Randomized and non-
randomized trial studies, including cohort studies,
case-control studies, before and after, and time-series
analyses. We excluded abstracts of scientific meetings
and conferences, research letters, qualitative studies,
letters to the editor, reviews, case reports, and case series.
Types of participants and settings HCWs delivering
intravenous therapies and infusions, or drawing blood
(venipuncture). We excluded all studies addressing HCWs
in non-healthcare settings (e.g. dental clinics, drawing
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blood at home, or home-based IV therapies). We excluded
studies of HCWs delivering intramuscular, intradermal,
subcutaneous, articular, intra-cardiac, and intra-peritoneal
injections. We excluded studies of blood drawing through
capillary sampling (i.e. using lancets).
Types of interventions Introduction into the healthcare
setting of a safety device to replace conventional intra-
venous and/or phlebotomy devices. We included passive
but not active devices given the evidence showing the
higher efficacy of the former over the latter in reducing
NSI [24]. Unlike active devices, passive devices activates
automatically during device use and therefore do not re-
quire additional steps to initiate the safety mechanism.
The intervention could have been accompanied by train-
ing of HCWs on how to use the safety-engineered
devices and/or by a surveillance system to monitor im-
plementation of the new devices.
Examples of eligible intravenous-related safety devices
include: needle-free (or “needle-less”) IV systems, Luer-
activated IV administration systems, safe IV catheters
with blunt cannula replacing sharp needle, blunt
implantable port needles and Needle-less adaptors, and
guarded arterio-venous fistula needles. Examples of
eligible phlebotomy-related safety devices include: blunt-
fill cannulae, vacuum-tube blood collection devices,
safety winged butterfly steel needles, and self-retracting
and/or self-sheathing (recapping) blood syringes. Ineligible
devices include intramuscular, intradermal, subcutaneous,
articular, intra-cardiac, and intra-peritoneal needles/syrin-
ges. We included studies assessing the introduction of
both eligible and ineligible devices, as long as they
reported data for eligible devices separately. Additionally,
we included studies in which both safety-engineered intra-
venous devices and safety-engineered phlebotomy devices
were introduced as long as they reported separate data for
these two types of devices.
Types of comparisons Traditional/conventional non-
safety device, such as the ‘single use disposable syringes’ ,
as the comparators.
Outcomes of interest NSI injuries among HCWs as
well as HBV, HCV, and/or HIV infections following a
NSI among HCWs.
Literature search
We used the OVID interface to electronically search
MEDLINE, EMBASE, CINHAL, and Cochrane Central
Register of Controlled Trials (CENTRAL). The searches
covered the period beginning with the database incep-
tion date and October 2013. We used no language or
date restrictions. The Appendix lists the search strategies
employed for each database. In addition, we reviewed
the references lists of relevant papers, searched personal
files for both published and unpublished studies, and
contacted experts in the field.
Selection process
Four reviewers participated in calibration exercises to
clarify the eligibility criteria. Then, they screened the
titles and abstracts of identified citations for potential
eligibility in duplicate (i.e., each citation was screened by
two reviewers) and independently using the above
described eligibility criteria. We retrieved the full text
for any citation judged as potentially eligible by at least
one reviewer. Then, the reviewers screened the full texts
for eligibility, in duplicate (i.e., each full text was screened
by two reviewers) and independently. They used a
standardized, pilot-tested full-text screening form. They
compared their results and resolved any disagreements
through discussion, or with the help of a third reviewer.
Data extraction and management process
Reviewers extracted data from the eligible studies in a
duplicate and independent fashion using a pilot-tested
and standardized data-extraction form. They resolved
disagreements by discussion or with the help of a third
reviewer. For non-English papers, we obtained the trans-
lation via Google Translate®.
We extracted the following information from each
eligible study: the specific attributes and mode of action
of the safety-engineered device; the study design; the
characteristics of the participants and of the setting; the
intervention employed; the control; the outcomes
assessed; the funding source; and disclosures of potential
conflicts of interest.
Risk of bias assessment in the included studies
Reviewers assessed the risk of bias in each included ran-
domized controlled trials in duplicate and independently
using the Cochrane risk of bias tool. They resolved all
disagreements by discussion or with the help of a third
reviewer. The tool includes an assessment of the following
criteria for randomized studies: inadequate sequence
generation; inadequate allocation concealment; lack of
blinding of participants, providers, data collectors, out-
come adjudicators, and data analysts; incompleteness of
outcome data; selective outcome reporting; and other bias.
As for the non-randomized studies, we used the following
criteria for assessing the risk of bias: failure to develop
and apply appropriate eligibility criteria; flaws in the meas-
urement of exposure/intervention; flaws in the measure-
ment of the outcome(s) of interest; failure to adequately
account for, and control for confounding; and incomplete
follow-up [25]. We judged each potential source of bias as
“high”, “low”, or “unclear”.
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Data synthesis
For categorical data, we calculated for each study the
risk ratio (RR) then pooled the results across studies using
a random-effects model. We evaluated heterogeneity
across studies using the I2 test, and considered it to be
present when I2 is greater than 50 %. Finally, we planned
to create inverted funnel plots in order to check for
possible publication bias.
Sensitivity analysis
We identified one study that assessed devices for intraven-
ous and/or phlebotomy procedures, in addition to intra-
muscular, subcutaneous, and/or intradermal injection
procedures, without providing outcome data separately
for the different procedures [26]. In a post-hoc decision,
we included these studies in the main analysis, but
excluded them from a sensitivity analysis, in order to
determine their impact on the final results.
Subgroup analysis
In order to explain any identified heterogeneity, we
planned to conduct subgroup analyses based on the
following factors: type of procedure for which the device
was intended (intravenous or phlebotomy), the type of
the device itself, the level of expertise and skills of
HCWs, and the time of the injury (before, during, or
after the procedure).
Quality of evidence assessment
We assessed the quality of evidence by outcome, using
the GRADE methodology [27]. We then generated a
GRADE Evidence Profile to summarize the statistical




Figure 1 shows the study flow diagram. Out of a total of
6566 identified citations, we assessed 46 full texts for
eligibility. Of these, we included 22 studies, and excluded
the remaining 26 for the following reasons (see
Additional file 1: Table S1): lacking a control or standard
(conventional device) to which the exposure (safety-engi-
neered device) data can be compared to (n = 6) [28–33],
not involving any actual intervention and being more of a
commentary type of study or using simple observa-
tion (n = 5) [34–38], being a review, an abstract, or a
non-original research paper reporting data from
another paper (e.g., magazine articles and monthly is-
sues of hospital reports) (n = 4) [39–42], not reporting
any data on NSI rates but rather HCWs’ evaluation
of the implemented device or its practicality (n = 4)
[43–46], lacking data for the pre- or the post- inter-
vention period (n = 2) [47, 48], lacking sufficient data
on study design, population, and device implemented
(n = 2) [31, 49], reporting economic analysis and cost-
relevant data (n = 1) [50], not reporting separate data
for different procedures (e.g., reporting overall drop
in NSI rates where more than one safety device was
implemented for different procedures) (n = 1) [51],
and having the implemented devices as non-safety-
engineered devices (n = 1) [52]. One of the studies
was reported in two peer-reviewed papers (duplicate
publication) [5, 6].
Study characteristics
Additional file 2: Table S2 provides a listing of the
twenty-two included studies with detailed description of
their characteristics. We summarized these characteristics
in the subsequent sections.
Types of injection
Out of the 22 included studies, twelve studies assessed
the introduction of IV safety devices [53–64], five studies
assessed the introduction of phlebotomy safety devices
[5, 26, 65–67], and five studies assessed the simultaneous
introduction of IV and phlebotomy safety devices [68–72].
Four of the studies of the “IV safety devices” category also
reported data for subcutaneous, intramuscular, and/or
intradermal injection devices separately [68, 70–72]. Five
studies of the “phlebotomy safety devices” category also
reported data for subcutaneous, intramuscular, and/or
intradermal injection devices [26, 68, 70–72], with one of
these studies [26] not reporting data separately.
Brands of devices
Sixteen out of the 22 studies specified the brand name
and/or the manufacturing company of the implemented
device(s): VanishPoint™ by Retractable Technologies, Inc
[72], SafetyGlide™ needles, SafetyGlide TNT insulin units
and blunt fill cannulae by Becton-Dickinson [26], Eclipse™,
Saf-T E-Z Set™,Preserts™, and Insyte Autoguard™ by
Becton Dickinson [71], Surshield™and Versatus-S™ by
Terumo [71], Provent Plus™ and Protective Plus™ by
Smiths Medical [71], Safety-Lok™ by Becton Dickinson
[6, 59, 67], Saf-T Clik™ by Ryan Medical, Inc [65], Clear-
link System™ by Baxter Healthcare Corp [53]., Interlink
System™ by Baxter Healthcare Corp [54, 56–60, 63].,
MasterGuard Anti-Stick Needle Protector™ by Medisys-
tems Corp [66]., Safesite System™ by Braun Medical, Inc
[64], Lifeshield™ by Abbott Laboratories [56], Saf-Site™ by
Burron Medical [56], Punctur-Guard™ by Bio-Plexus, Inc
[6], and Venipuncture Needle-Pro™ by Smiths Medical [6].
The remaining six studies mentioned neither the brand
name of the device nor the manufacturer or supplier.
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Funding
Nine out of the 22 studies reported their funding
sources; these include:
1- Becton Dickinson; [26]
2- National Institute of Allergy and Infectious Diseases;
the Centers for Disease Control and Prevention; and
the Prevention Epicenters; [70]
3- The Directorate General of Public Health of the
Autonomous Community of Valencia, Spain; [71]
4- The Educational Resource Centers, Inc, at the
National Institute for Occupational Safety and
Health; [57]
5- New York State Department of Health and Braun
Medical, Inc. [64]
6- The Centers for Disease Control and Prevention/
National Institute of Occupational Safety and
Health; Mr. William E. Flanagan Jr; [55]
7- The French Ministry of Health and la Mutuelle
Nationale des Hospitaliers and the following
companies: Becton-Dickinson, Bristol-Myers-Squibb,
Glaxo Wellcome, Johnson & Johnson Medical, Ken-
dall Sherwood David & Geck, MAPA Hutchinson,
Merck Sharp & Dohme Chibret, Sanofi Winthrop,
SIMS France, and Terumo; [69]
8- Baxter Healthcare Corporation [53, 59].
Disclosure of conflicts of interest
Only two studies had their authors declare in writing at
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Full-text articles excluded, 
with reasons n = 26 
• No control group (n=6) 
• No intervention (n=5)  
• Non-original research 
(n=4)  
• No outcome of interest 
(n=4)
• No data for pre- or post-
intervention period 
(n=2)  
• No sufficient data on 
study design, 
population, or device 
(n=2)  
• Economic analysis 
(n=1) 





Studies included in 
qualitative synthesis
n = 22
Studies included in 
quantitative synthesis 
(meta-analysis)
n = 21 
Fig. 1 PRISMA flow diagram
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The remaining 20 studies did not report any disclosures
about potential conflicts of interest.
Study design
Only one study was a randomized controlled trial [56]
and assessed the introduction of IV safety devices with a
prospective data collection design. The remaining 21 stud-
ies were non-randomized employing a before-and-after
study design. Of these 21 studies, four collected data retro-
spectively throughout the study period [53, 57, 62, 68],
three collected data retrospectively for the “before” period
and prospectively for the “after” period [54, 64, 66], eight
collected data prospectively throughout the study period
[26, 55, 59, 67, 69–72], and one collected data retrospect-
ively for the “before period” but was unclear with regards
to the “after” period [65]. The five remaining non-
randomized studies did not specify their data collection
approach [6, 58, 60, 61, 63].
Participants
The included studies involved hospital-based nursing
staff (n = 20) [6, 26, 53–64, 67–72], clinical staff of
hospital-affiliated hemodialysis units (n = 1) [66]
laboratory personnel and non-nursing phlebotomists
(n = 7) [6, 55, 57, 62, 65, 68, 70], ancillary/outpatient
staff (n = 3) [26, 55, 70], housekeeping staff (n = 7)
[53, 57, 58, 62, 70–72], hospital aide (n = 1) [58],
surgical and operation room staff (n = 7) [26, 53, 58,
59, 62, 68, 70], ambulatory care HCWs (n = 1) [60],
attending physicians (n = 9) [26, 53, 58, 59, 62, 68,
70–72], interns, residents, and fellows (n = 6) [6, 26,
57, 59, 70, 71], medical students (n = 3) [6, 59, 68],
and nursing students (n = 2) [59, 71].
Settings
The included studies were all conducted in high-income
countries, as follows: United States (n = 13) [6, 54–57,
59–62, 64–66, 70], Canada (n = 2) [53, 63], France (n = 2)
[67, 69], United Kingdom (n = 1) [26], Germany (n = 1)
[68], Spain (n = 1) [71], Australia (n = 1) [72], and New
Zealand (n = 1) [58].
Intervention/exposure
Interventions involved the introduction of a variety of IV
and/or phlebotomy safety devices, specified above under
“Device brand”, into a healthcare setting. In 17 out of
the 22 included studies, the HCWs received some form
of educational intervention and/or training on the use of
the newly implemented device [26, 54–57, 59–64, 66–
68, 70–72].
Control/comparison
Nineteen out of the 22 included studies mentioned that
the standard of comparison to which the exposure was
compared, was the use of “conventional”, “standard”,
“traditional”, or “alternative” devices for the corresponding
IV and/or Phlebotomy procedure(s) under study [6, 53–
56, 59–71] Only three studies did not specify the nature of
the device used as control [57, 58, 72]. Additionally, one
of the studies used “standard education” and “enhanced
training” in both the control and exposure groups to make
the availability of the safety device(s) under study the only
variable between the two groups [26].
Outcomes
All of the included studies assessed NSI among HCWs
with and without the introduction of a safety device.
Only one of the included studies reported data narra-
tively on patient infection(s) with blood-borne pathogens
(HBV, HCV, and HIV) upon acquiring NSIs [68]. All
other studies reported no valuable data on any of the
outcomes of interest other than NSIs.
Risk of bias within studies
Additional files 3 and 4: Table S3 and S4 detail the risk
of bias assessment and the underlying judgments for the
included randomized study [56], and the remaining non-
randomized studies respectively. These assessments are
summarized graphically in Fig. 2 (the randomized study),
Fig. 3 (non-randomized studies of intravenous devices)
and Fig. 4 (non-randomized studies of phlebotomy
devices).
Meta-analysis for intravenous safety devices
The eligible studies that reported NSI data used three
main types of statistics: incidence of NSI per HCW (n = 5)
[55, 57, 68, 70, 72], incidence of NSI per devices used or
procedures performed (n = 4) [54, 58, 69, 71], and
incidence of NSI per year (n = 6) [53, 59–61, 63, 64]. The
randomized study reported the incidence of NSIs per
patient-days [56]. We performed distinct meta-analyses
for these different statistics.
We did not include one of the studies in any meta-
analysis because it did not report the statistical data in
any of the three types of statistics mentioned above [62].
That study reported a 39 % decrease of needle-stick
injuries over a 4-year period following the introduction
of a safety-designed needle-free IV access system.
NSI per HCW
The meta-analysis of four studies [55, 57, 68, 70, 72]
resulted in a pooled relative risk of 0.28 [95 % CI 0.13,
0.59]. The I2 value was 83 % (Fig. 5). We were not con-
cerned about heterogeneity given most studies showed
benefit and the heterogeneity reflected the variation in
the degree of that benefit. We rated up the quality of
evidence from low (observational data) to moderate due
Ballout et al. BMC Health Services Research  (2016) 16:458 Page 6 of 18
to the large effect size, while acknowledging some
concern about risk of bias in the included studies.
NSI per device or procedure performed
The meta-analysis of four studies [54, 58, 69, 71] re-
sulted in a pooled relative risk of 0.34 [95 % Confidence
Interval (CI) 0.08,1.49]. The I2 value was 80 % (Fig. 6).
We were not concerned about heterogeneity given most
studies showed benefit and the heterogeneity reflected
the variation in the degree of that benefit. While the
large observed effect would typically warrant rating up
the quality of evidence from low to moderate, we did
not do so because of the imprecision of the results. We
judged the quality of evidence as low.
NSI per year
The meta-analysis of six studies [53, 59–61, 63, 64]
resulted in a pooled relative risk of 0.28 [95 % CI 0.16,
0.49]. The I2 value was 58 % (Fig. 7). We were not
concerned about heterogeneity given most studies
showed benefit and the heterogeneity reflected the
variation in the degree of that benefit. We rated up the
quality of evidence from low (observational data) to
moderate due to the large effect size, while acknowledg-
ing some concern about risk of bias in the included
studies.
Fig. 2 Risk of bias summary diagram for the single included randomized
study assessing IV safety devices
Fig. 3 Risk of bias summary diagram for all the included non-
randomized studies assessing IV safety devices
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In a separate analysis, we included the only
randomized controlled trial [56] whose relative risk
ratio turned out to be 0.57 [95 % CI 0.27, 1.22] (Fig. 8).
We rated the quality of evidence as low due to concern
about risk of bias and imprecision.
Meta-analysis for phlebotomy safety devices
The eligible studies that reported NSI data used two main
types of statistics: incidence of NSI per HCW (n = 3)
[68, 70, 72], and incidence of NSI per devices used or
procedures performed (n = 7) [6, 26, 65–67, 69, 71]. We
performed distinct meta-analyses for these different statis-
tics. We excluded only one study from the meta-analysis
because it had an interrupted-time series design (ITS)
[67]. That study reported an overall reduction of 48 % in
percutaneous injuries per 100,000 phlebotomies performed.
NSI per HCW
The meta-analysis of two studies [68, 70, 72] resulted in
a pooled relative risk of 0.57 [95 % CI 0.38, 0.84]. The I2
value was 0 % (Fig. 9). We rated up the quality of
evidence from low (observational data) to moderate due
to the large effect size.
NSI per device or procedure performed
The meta-analysis of six studies [6, 26, 65, 66, 69, 71]
resulted in a pooled relative risk of 0.52 [95 % CI 0.38,
0.72]. The I2 value was 13 % (Fig. 10). We rated up the
quality of evidence from low (observational data) to
moderate due to the large effect size.
Other outcomes
One study [68] reported blood-borne pathogen infection
rates in patients, and not HCWs, for the year before
introducing the safety devices and in the year afterwards.
It stated: “Infection with HBV, HCV or HIV in needle-
stick index patients was high in both years, with a preva-
lence of 6.7 % in 2007 and 9.0 % in 2009 for all three
blood-borne viruses together”. No information about
statistical significance was provided. Another study [72]
stated: “No significant increase in bloodstream infections
was detected during the study period”, without any
numerical evidence included to support that statement.
None of the other studies reported similar data relevant
to these other outcomes of interest such as reduction in
HBV, HCV, and HIV infections among HCWs and/or
patients, or reduction in any other blood-borne infection
in HCWs and/or patients.
Additional analyses
The post-hoc sensitivity analysis excluding the one study
not providing outcome data separately for the different
types of procedures [26], did not substantively impact
the results of the main analysis. We were not able to
conduct planned subgroup analyses because of the
relatively small number of studies per analysis. Another
reason was the lack of sufficient and clearly reported
data on some of the factors we planned to conduct the
analyses based upon such as: the type of device, the level
of expertise of HCWs using the devices, the time of
Fig. 4 Risk of bias summary diagram for all the included non-
randomized studies assessing Phlebotomy (blood-drawing)
safety devices
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injury (before, during, or after the injection/withdrawal),
and the mechanism of action/use of the specific device
under study.
Discussion
In summary, we identified moderate quality evidence
that intravenous safety devices and phlebotomy safety
devices reduce the risk of NSIs amongst HCWs per-
forming such procedures. We did not identify substantial
evidence about the effects on HCWs infection(s) with
blood-borne pathogens (HBV, HCV, and HIV).
We have identified a systematic review published in
2006 addressing the same question [73]. That review
concluded that “a reduction in injury rate of ~50–60 %
might be possible with phlebotomy devices”, which is
less than the current review’s estimates. We believe our
findings are more reliable for a number of reasons. First,
that review addressed the efficacy of safety devices with
either active or passive safety features. Our review fo-
cused on passive devices given there is evidence showing
their higher efficacy compared with active devices [24].
Additional advantages of our review include the use of a
systematic approach to study selection and data abstrac-
tion, the assessment of risk of bias of included studies,
and the grading of the quality of evidence by outcome
using the GRADE methodology. The reviewers included
seven studies in common with our review [56, 57, 59,
63, 65, 67, 70]. They also included four studies that we
excluded for different reasons: the lack of an actual im-
plementation of a safety device [38], not reporting data
separately for separate procedures [51], being an abstract
and not a published full-text [42], and not reporting
comparative data for the conventional device [30]. Thus,
compared with the 2006 review, our systematic review
included 15 additional studies [6, 26, 53–55, 58, 60–62,
64, 66, 68, 69, 71, 72].
We have identified a more recently published
Cochrane systematic review addressing a related but dis-
tinct research question [74]. In fact, that review had a
wider scope and addressed types of safety devices other
than intravenous and/or phlebotomy (e.g., sharps
containers for on-spot disposal of used sharps) and in
settings other than hospitals (e.g., dental clinics). Also,
the Cochrane review included studies of safety-devices
with active features, which we excluded as justified
above under ‘Types of interventions’. Unlike our review,
the Cochrane review excluded before and after studies.
The Cochrane review found very low quality evidence
that safety-engineered blood-collection (i.e., phlebotomy)
and IV devices can lower NSIs compared to the conven-
tional non-safety-engineered devices. However, one of
their two estimates of relative risk based on one trial
was higher than ours (0.62 (95 % CI 0.27 to 1.41) while
their other estimate of relative risk based on one
controlled before and after study was lower than ours
(0.06 (95 % CI 0.0 to 1.09). This discrepancy between
the two reviews is due to the different eligibility criteria,
particularly in terms of our inclusion of six non-
controlled before and after studies [53–55, 57, 61, 72].
There are two main explanations for the differences in
rating the quality of evidence between the Cochrane
review and our review. First, the inter-rater reliability of
using the GRADE approach for assessing the quality of
evidence is not perfect, with an inter-rater reliability
(IRR) of 0.72 among members of the GRADE working
group. Second, there is a debate on how to rate the
Fig. 5 Needle stick injury data of the studies assessing IV safety devices reported as rates of injuries per number of healthcare workers
Fig. 6 Needle stick injury data of the studies assessing IV safety devices reported as rates of injuries per number of devices or procedures performed
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quality of evidence from observational studies, with
some advocating rating evidence from studies using ITS
analysis as moderate quality [75]. Our approach was to
start with low quality rating for the evidence from
uncontrolled before and after studies, then rating them
up for large effect [76].
Few studies have assessed the use of these devices
from the economic point of view. Griswold et al. [50]
assessed StatLock™, a safety-engineered device designed
to protect HCWs placing central venous catheters from
NSIs. The authors estimated that the use of the device
could spare hospitals a cost of $2723 incurred by each
NSI acquired by a HCW, and could have saved a mini-
mum of $57,183 over the evaluated four-year study period.
Yassi et al. conducted economic-benefit and cost effective-
ness analyses for the use of safety devices in intravenous
and phlebotomy procedures [63]. They found that the
introduction of the safety Interlink system may increase
cost to the hospital, but judged that any incremental cost
would be offset by the avoidance of costs related to NSIs
and infections. One study evaluated the ease of use of the
safety devices. Griswold et al. found that surgical residents
“seemed to prefer using sutures over the StatLock device”
[50]. One participant suggested the need for additional
practice with the device before using it in a clinical setting.
The main strength of this review is the use of a rigorous
methodology for conducting systematic reviews. The major
limitation pertained to the lack of original studies assessing
the effects of the safety devices on blood borne infections
(particularly HIV, HBV, and HCV) amongst workers
healthcare. Also the quality of evidence for some of the
outcomes of interest was low, suggesting the need for
further studies to strengthen that quality.
Conclusion
The findings of this review have significant implications
for HCWs. The introduction into the healthcare setting
of safety-engineered devices for intravenous and/or phle-
botomy procedures will likely reduce NSIs to HCWs.
However, the decision to introduce these devices into
healthcare facilities should take into account the costs
related to the purchase, training, use of these devices
and the impact of their introduction on the sharps waste
generated and its safe management. These devices are
typically introduced as part of a wider injection safety
program, including: education about the risks associated
with accidental injuries, training in the safety devices,
surveillance and reporting of NSIs, immunization
against HBV, post exposure prophylaxis and appropriate
sharps waste management. Also, the HCWs would need
to be involved in evaluating and selecting the proper
devices.
The findings also have important implications for
future research. There is a need to further build the
evidence base for safety-engineered devices for intraven-
ous and/or phlebotomy procedures. There is also a need
for studies assessing the economic impact of these
devices, the ease of their use in practice, as well as their
acceptability by HCWs. Finally, all included studies were
conducted in high income countries; there is a need to
undertake such studies in middle- and low- income
countries where unsafe injection practices and accidental
needle stick injuries in HCWs are still prevalent.
Appendix
Detailed description of the search strategy used with the
MeSH terms and keywords employed.
Fig. 7 Needle stick injury data of the studies assessing IV safety devices reported as rates of injuries per year
Fig. 8 Needle stick injury data of the randomized trial assessing IV safety devices, reported as rates of injuries per patient-days
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Search strategies used to detect relevant papers
Search strategy used in Medline:
1. Health Personnel/
2. Personnel, Hospital/
3. ((Healthcare or health-care or (health adj care))
adj2 worker*).mp.
4. Paramedic*.mp.
5. ((medical or nurs*or ancillary) adj2 staff*).mp.







13. exp Needlestick Injuries/
14. exp Accidents, Occupational/and (syringe* or
needle* or inject*).mp.
15. (injur* adj3 (syringe* or needle* or inject*)).mp.
16. exp Accidents, Occupational/and (syringe* or
needle* or inject*).mp.
17. exp Accident Prevention/and (syringe* or needle*
or inject*).mp.
18. (blood adj3 collection adj3 (syringe* or needle* or
system* or device* or material* or product*
or set*)).mp.
19. ((need-less or needless or needle-free or needlefree)
adj3 (syringe* or needle* or system* or device* or
material* or product* or set* or inject*)).mp.
20. (Single adj3 “use” adj3 (syringe* or needle* or
system* or device* or material* or product*
or set* or inject*)).mp.
21. (prevent* adj3 (syringe* or needle* or system* or
device* or material* or product* or set*
or inject*)).mp.
22. (reuse adj3 (syringe* or needle* or system* or
device* or material* or product* or set*
or inject*)).mp.
23. (exp Equipment Reuse/or exp Disposable
equipment/) and (syringe* or needle* or system*
or device* or material* or product* or set*
or inject*).mp.
24. (Disposable adj2 equipment* adj3 (syringe*
or needle* or inject*)).mp.
25. ((prefill* or pre-fill*) adj3 (syringe* or needle*
or inject*)).mp.












38. ((prefill* or pre-fill*) adj2 syringe*).mp.
Fig. 9 Needle stick injury data of the studies assessing phlebotomy safety devices reported as rates of injuries per number of healthcare workers
Fig. 10 Needle stick injury data of the studies assessing phlebotomy safety devices reported as rates of injuries per number of devices or
procedures performed
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39. “BD Hypak”.mp.
40. “Safety-Lok”.mp.





















Search strategy used in EMBASE:
1 Health Personnel/
2 Personnel, Hospital/
3 ((Healthcare or health-care or (health adj care))
adj2 worker*).mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
4 Paramedic*.mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name,
keyword]
5 ((medical or nurs*or ancillary) adj2 staff*).mp.
[mp = title, abstract, subject headings, heading
word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade
name, keyword]
6 (Medical adj2 laboratory adj2 techn*).mp. [mp = title,
abstract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug
manufacturer, device trade name, keyword]
7 Pharmacist*.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
8 physician*.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
9 Hospitalist*.mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name,
keyword]
10 internist*.mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device
trade name, keyword]
11 doctor*.mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device
trade name, keyword]
12 Phlebotomist*.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
13 exp Needlestick Injuries/
14 exp Accidents, Occupational/and (syringe* or
needle* or inject*).mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
15 (injur* adj3 (syringe* or needle* or inject*)).mp.
[mp = title, abstract, subject headings, heading
word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade
name, keyword]
16 exp Accidents, Occupational/and (syringe* or
needle* or inject*).mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device
trade name, keyword]
17 exp Accident Prevention/and (syringe* or needle*
or inject*).mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name,
keyword]
18 (blood adj3 collection adj3 (syringe* or needle* or
system* or device* or material* or product* or
set*)).mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device
trade name, keyword]
19 ((need-less or needless or needle-free or needlefree)
adj3 (syringe* or needle* or system* or device*
or material* or product* or set* or inject*)).mp.
[mp = title, abstract, subject headings, heading
word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade
name, keyword]
20 (Single adj3 “use” adj3 (syringe* or needle* or system*
or device* or material* or product* or set* or
inject*)).mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title, device
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manufacturer, drug manufacturer, device trade name,
keyword]
21 (prevent* adj3 (syringe* or needle* or system* or
device* or material* or product* or set* or
inject*)).mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device
trade name, keyword]
22 (reuse adj3 (syringe* or needle* or system* or device*
or material* or product* or set* or inject*)).mp.
[mp = title, abstract, subject headings, heading word,
drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword]
23 (exp Equipment Reuse/or exp Disposable
equipment/) and (syringe* or needle* or system* or
device* or material* or product* or set* or inject*).mp.
[mp = title, abstract, subject headings, heading
word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade
name, keyword]
24 (Disposable adj2 equipment* adj3 (syringe* or
needle* or inject*)).mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
25 ((prefill* or pre-fill*) adj3 (syringe* or needle* or
inject*)).mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade
name, keyword]
26 (Autopen or auto-pen).mp. [mp = title, abstract,
subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufac-
turer, device trade name, keyword]
27 “Vetter Lyo-ject”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
28 Vasceze.mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device
trade name, keyword]
29 Sterimatic.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
30 “Safe-Point”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
31 “Needle-Pro”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
32Hypak.mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device
trade name, keyword]
33 VanishPoint.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
34 “Slip-lock”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
35 Luerlok.mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device
trade name, keyword]
36 “Bio-Set”.mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device
trade name, keyword]
37 “Auto-disposable syringe*”.mp. [mp = title, abstract,
subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer,
device trade name, keyword]
38 ((prefill* or pre-fill*) adj2 syringe*).mp. [mp = title,
abstract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug
manufacturer, device trade name, keyword]
39 “BD Hypak”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
40 “Safety-Lok”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
41 (Kendall’s adj2 Monoject).mp. [mp = title, abstract,
subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer,
device trade name, keyword]
42 “autodestruct syringe”.mp. [mp = title, abstract,
subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer,
device trade name, keyword]
43 SoloShot.mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device
trade name, keyword]
44 “Monodose syringe*”.mp. [mp = title, abstract,
subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer,
device trade name, keyword]
45 “Unifine pentip*”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
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title, device manufacturer, drug manufacturer,
device trade name, keyword]
46Autoject.mp. [mp = title, abstract, subject headings,
heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device
trade name, keyword]
47 (ultrasafe adj passive adj delivery adj system).mp.
[mp = title, abstract, subject headings, heading word,
drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword]
48 “Tip-Lok”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
49 “Gettig Guard”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
50 “Inviro SNAP!”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
51 “Maxxon safety syringe*”.mp. [mp = title, abstract,
subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer,
device trade name, keyword]
52 “monoject magellan”.mp. [mp = title, abstract,
subject headings, heading word, drug trade name,
original title, device manufacturer, drug
manufacturer, device trade name, keyword]
53 “needle-pro”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
54 “point-lok”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
55 “wandplus”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
56 “safetyglide”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
57 “safety wand”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,
device trade name, keyword]
58 “powder ject”.mp. [mp = title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer,




Search strategy used in CENTRAL:
1. MeSH descriptor: [Health Personnel] explode all trees
2. MeSH descriptor: [Personnel, Hospital] explode all
trees
3. ((Healthcare or health-care or (health near/1 care))
near/2 worker*): ti,ab,kw (Word variations have
been searched)
4. Paramedic*: ti,ab,kw (Word variations have been
searched)
5. ((medical or nurs*OR ancillary) near/2 staff*):ti,ab,kw
(Word variations have been searched)
6. (Medical near/2 laboratory near/2 techn*):ti,ab,kw
(Word variations have been searched)
7. Pharmacist*:ti,ab,kw (Word variations have been
searched)
8. physician*:ti,ab,kw (Word variations have been
searched)
9. Hospitalist*:ti,ab,kw (Word variations have been
searched)
10. internist*:ti,ab,kw (Word variations have been
searched)
11. doctor*:ti,ab,kw (Word variations have been
searched)
12. Phlebotomist*: ti,ab,kw (Word variations have been
searched)
13. MeSH descriptor: [Needlestick Injuries] explode all
trees
14. MeSH descriptor: [Accidents, Occupational]
explode all trees
15. (syringe* or needle* or inject*): ti,ab,kw (Word
variations have been searched)
16. #14 and #15
17. (injur* near/3 (syringe* or needle* or inject*)):
ti,ab,kw (Word variations have been searched)
18. MeSH descriptor: [Accident Prevention] explode
all trees
19. (syringe* or needle* or inject*): ti,ab,kw (Word
variations have been searched)
20. #18 and #19
21. (blood near/3 collection near/3 (syringe* or needle*
or system* or device* or material* or product* or
set*)): ti,ab,kw (Word variations have been
searched)
22. ((need-less or needless or needle-free or needle-
free) near/3 (syringe* or needle* or system* or
device* or material* or product* or set* or inject*)):
ti,ab,kw (Word variations have been searched)
23. (Single near/3 “use” near/3 (syringe* or needle* or
system* or device* or material* or product* or set*
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or inject*)):ti,ab,kw (Word variations have been
searched)
24. (prevent* near/3 (syringe* or needle* or system* or
device* or material* or product* or set* or
inject*)):ti,ab,kw (Word variations have been
searched)
25. (reuse near/3 (syringe* or needle* or system* or
device* or material* or product* or set* or inject*)):
ti,ab,kw (Word variations have been searched)
26. MeSH descriptor: [Equipment Reuse] explode
all trees
27. MeSH descriptor: [Disposable Equipment] explode
all trees
28. #26 or #27
29. (syringe* or needle* or system* or device* or
material* or product* or set* or inject*): ti,ab,kw
(Word variations have been searched)
30. #28 and #29
31. (Disposable near/2 equipment* near/3 (syringe* or
needle* or inject*)): ti,ab,kw (Word variations have
been searched)
32. ((prefill* or pre-fill*) near/3 (syringe* or needle* or
inject*)): ti,ab,kw (Word variations have been
searched)
33. ((prefill* or pre-fill*) near/3 (syringe* or needle* or
inject*)): ti,ab,kw (Word variations have been
searched)
34. (Autopen or auto-pen): ti,ab,kw (Word variations
have been searched)
35. “Vetter Lyo-ject”: ti,ab,kw (Word variations have
been searched)
36. Vasceze: ti,ab,kw (Word variations have been
searched)
37. Sterimatic: ti,ab,kw (Word variations have been
searched)
38. “Safe-Point”: ti,ab,kw (Word variations have been
searched)
39. “Needle-Pro”: ti,ab,kw (Word variations have been
searched)
40. Hypak:ti,ab,kw (Word variations have been searched)
41. VanishPoint: ti,ab,kw (Word variations have been
searched)
42. Slip-lock: ti,ab,kw (Word variations have been
searched)
43. Luerlok: ti,ab,kw (Word variations have been
searched)
44. “Bio-Set”: ti,ab,kw (Word variations have been
searched)
45. “Auto-disposable syringe*”: ti,ab,kw (Word
variations have been searched)
46. ((prefill* or pre-fill*) near/3 syringe*): ti,ab,kw
(Word variations have been searched)
47. “BD Hypak”: ti,ab,kw (Word variations have been
searched)
48. “Safety-Lok”: ti,ab,kw (Word variations have been
searched)
49. (Kendall’s adj2 Monoject): ti,ab,kw (Word
variations have been searched)
50. “autodestruct syringe”: ti,ab,kw (Word variations
have been searched)
51. SoloShot: ti,ab,kw (Word variations have been
searched)
52. “Monodose syringe*”: ti,ab,kw (Word variations
have been searched)
53. “Unifine pentip*”: ti,ab,kw (Word variations have
been searched)
54. Autoject: ti,ab,kw (Word variations have been
searched)
55. (ultrasafe near passive near delivery near system):
ti,ab,kw (Word variations have been searched)
56. “Tip-Lok”: ti,ab,kw (Word variations have been
searched)
57. “Gettig Guard”: ti,ab,kw (Word variations have
been searched)
58. “Inviro SNAP!”: ti,ab,kw (Word variations have
been searched)
59. “Maxxon safety syringe*”: ti,ab,kw (Word variations
have been searched)
60. “monoject magellan”: ti,ab,kw (Word variations
have been searched)
61. “needle-pro”: ti,ab,kw (Word variations have been
searched)
62. “point-lok”: ti,ab,kw (Word variations have been
searched)
63. “wandplus”: ti,ab,kw (Word variations have been
searched)
64. “safetyglide”: ti,ab,kw (Word variations have been
searched)
65. “safety wand”: ti,ab,kw (Word variations have been
searched)
66. “powder ject”: ti,ab,kw (Word variations have been
searched)
67. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
or #10 or #11 or #12
68. #13 or #16 or #17 or #20 or #21 or #22 or #23 or
#24 or #25 or #30 or #31 or #32 or #33 or #34 or
#35 or #36 or #37 or #38 or #39 or #40 or #41 or
#42 or #43 or #44 or #45 or #46 or #47 or #48 or
#49 or #50 or #51 or #52 or #53 or #54 or #55 or
#56 or #57 or #58 or #59 or #60 or #61 or #62 or
#63 or #64 or #65 or #66
69. #67 and #68
Search strategy used in CINAHL:
1 (MH “Health Personnel + ”)
2 (Healthcare or health-care or (health W care)) N2
worker*
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3 Paramedic*
4 (medical or nurs*or ancillary) N2 staff*







12 (MH “Needlestick Injuries”)
13 (MH “Occupational-Related Injuries”)
14 (MH “Accidents, Occupational”)
15 injur* N3 (syringe* or needle* or inject*)
16 (blood N3 collection) N3 (syringe* or needle* or
system* or device* or material* or product* or set*)
17 (need-less or needless or needle-free or needlefree)
N3 (syringe* or needle* or system* or device* or
material* or product* or set* or inject*)
18 Single N3 “use” N3 (syringe* or needle* or system* or
device* or material* or product* or set* or inject*)
19 prevent* N3 (syringe* or needle* or system* or
device* or material* or product* or set* or inject*)
20 (MH “Equipment Reuse”)
21 (MH “Disposable Equipment”)
22 (MH “Sharps Disposal”)
23 (MH ”Equipment Safety”)
24 (syringe* or needle* or system* or device* or
material* or product* or set* or inject*)
25 S20 OR S21 OR S22 OR S23
26 S24 AND S25
27Disposable N2 equipment* N3 (syringe* or needle*
or inject*)
28 (Disposable N2 equipment*) N3 (syringe* or
needle* or inject*)
29 Sharp*












42 (prefill* or pre-fill*) N2 syringe*
43 “Safety-Lok”
44 “BD Hypak”
45 Kendall’s N2 Monoject
46 “autodestruct syringe”

















64 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR
S8 OR S9 OR S10 OR S11
65 S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18
OR S19 OR S26 OR S27 OR S28 OR S29 OR S30
66 S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR
S37 OR S38 OR S39 OR S40 OR S42 OR S43 OR
S44 OR S45 OR S46 OR S47 OR S48 OR S50 OR
S51 OR S52 OR S53 OR S54 OR S55 OR S58 OR
S59 OR S60 OR S61 OR S62 OR S63 OR S65
67 S65 OR S66
68 S64 AND S67.
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